Fimasartan

ArtNr	HY-B0780-100mg
Hersteller	MedChem Express
CAS-Nr.	247257-48-3
Menge	100 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 50 mg 5 mg
Kategorie	Neuroscience Metabolism Cholesterol & Lipid Metabolism Neural Signaling Neural Adhesion Molecules Cell Biology Cytoskeleton Enzymes Other Fatty Acid Enzymes Inhibitors & Compound Libraries Small Molecules small GTPases Ras Subfamily
Typ	Inhibitors
Specific against	other
Purity	98.55
Citations	[1]Ryu S, et al. Fimasartan, anti-hypertension drug, suppressed inducible nitric oxide synthase expressions via nuclear factor-kappa B and activator protein-1 inactivation. Biol Pharm Bull. 2013;36(3):467-74.\|[2]Chi YH, et al. Pharmacological characterization of BR-A-657, a highly potent nonpeptide angiotensin II receptor antagonist. Biol Pharm Bull. 2013;36(7):1208-15.\|[3]Yang X, Sun J, Kim TJ, Kim YJ, Ko SB, Kim CK, Jia X, Yoon BW. Pretreatment with low-dose fimasartan ameliorates NLRP3 inflammasome-mediated neuroinflammation and brain injury after intracerebral hemorrhage. Exp Neurol. 2018 Dec;310:22-32.
Smiles	O=C1N(C(CCCC)=NC(C)=C1CC(N(C)C)=S)CC2=CC=C(C3=C(C4=NN=NN4)C=CC=C3)C=C2
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	BR-A-657
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Targets	Angiotensin Receptor; Apoptosis; NF-κB
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	501.65
Product Description	Fimasartan (BRA-657) is an orally effective angiotensin receptor AT1 non-peptide antagonist. Fimasartan has antihypertensive effects. Fimasartan improves neuroinflammation and brain injury mediated by NLRP3 inflammatome after intracerebral hemorrhage, and has neuroprotective effect. Fimasartan inhibits the expression of inducible nitric oxide synthase through the inactivation of NF-κB and activator protein-1[1][2][3].
Manufacturer - Research Area	Endocrinology; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease
Solubility	DMSO: ≥ 49 mg/mL
Manufacturer - Pathway	Apoptosis; GPCR/G Protein; NF-κB
Isoform	AT1 Receptor
Clinical information	Launched

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-B0780-100mg-safety-datasheet.pdf